The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-α (TNF-α) and TNF-α receptors during human endotoxemia

Blood

Volumn 94, Issue 7, 1999, Pages 2252-2258

  Dekkers, Pascale E P ^a   Lauw, Fanny N ^b   Ten Hove, Tessa ^b   Te Velde, Anje A ^b   Lumley, Philip ^b   Becherer, David ^b   Van Deventer, Sander J H ^b   Van Der Poll, Tom ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GI 5402; LIPOPOLYSACCHARIDE; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; ENDOTOXEMIA; GRANULOCYTE; HUMAN; HUMAN EXPERIMENT; INFLAMMATORY DISEASE; MALE; MONOCYTE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

EID: 0033215445     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2252.419k25_2252_2258     Document Type: Article

References (32)

1. Tracey KJ, Cerami A: Tumor necrosis factor, other cytokines and disease. Ann Rev Cell Biol 9:317, 1993
2. Kriegler M, Perez C, K DeFay, Albert I, Lu SD: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53:45, 1988
3. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M: A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:251, 1990
4. Black R A, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729, 1997
5. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Panel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733, 1997
6. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawama K:. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218, 1994
7. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL: Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370:555, 1994
8. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S: Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 370:558, 1994
9. Mullberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, Black RA, Mohler KM: A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 155:5198, 1995
10. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF: A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 181:1205, 1995
11. Solorzano CC, Ksontini R, Pruitt JH, Hess PJ, Edwards PD, Kaibara A, Abouhamze A, Auffenberg T, Galardy RE, Vauthey JN, Copeland EM III, Edwards CK III, Lauwers GY, Clare-Salzler M, MacKay SL, Moldawer LL, Lazarus DD: Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol 158:414, 1997
12. Solorzano CC, Ksontini R, Pruitt JH, Auffenberg T, Tannahill C, Galardy RE, Schultz GP, MacKay SL, Copeland EM, 3rd, Moldawer LL:. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 7:427, 1997
13. Gallea-Robache S, Morand V, Millet S, Bruneau JM, Bhatnagar N, Chouaib S, Roman-Roman S: A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 9:340, 1997
14. Hattori K, Hirano T, Ushiyama C, Miyajima H, Yamakawa N, Ebata T, Wada Y, Ikeda S, Yoshino K, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K: A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood 90:542, 1997
15. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA: An essential role for ectodomain shedding in mammalian development. Science 282:1281, 1998
16. Hooper NM, Karran EH, Turner AJ: Membrane protein secretases. Biochem J 321:265, 1997
17. Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM: Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest 97:2833, 1996
18. Bickett DM, Green MD, Berman J, Dezube M, Howe AS, Brown PJ, Roth JT, McGeehan GM: A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal Biochem 212:58, 1993
19. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97:713, 1996
20. Nerad JL, Griffiths JK, van der Meer JWM, Endres S, Poutsiaka DD, Keusch GT, Bennish M, Salam MA, Dinarello CA, Cannon JG. Interleukin-1β (IL-1γ), IL-1 receptor antagonist, and TNFα production in whole blood. J Leukoc Biol 52:687, 1992
21. Jansen J, van der Poll T, Levi M, ten Cate H, Gallati H, ten Cate JW, van Deventer SJ: Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. J Clin Immunol 15:45, 1995
22. Engelberts I, Stephens S, Francot GJM, van der Linden CJ, Buurman WA: Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 338:515, 1991
23. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J: Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFa and activates immune effector functions. Cytokine 7:251, 1995
24. Aversa G, Punnonen J, de Vries JE: The 26 kD transmembrane form of tumor necrosis factor a on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 177:1575, 1993
25. van der Poll T, Calvano SE, Kumar A, Braxton CC, Coyle SM, Barbosa K, Moldawer LL, Lowry SF: Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 86:2754, 1995
26. van der Poll T, Calvano SE, Kumar A, Coyle SM, Lowry SF: Epinephrine attenuates down-regulation of monocyte tumor necrosis factor receptors during human endotoxemia. J Leukoc Biol 61:156, 1997
27. van der Poll T, Coyle SM, Kumar A, Barbosa K, Agosti JM, Lowry SF: Down-regulation of surface receptors for TNF and IL-1 on circulating monocytes and granulocytes during human endotoxemia: Effect of neutralization of endotoxin-induced TNF activity by infusion of a recombinant dimeric TNF receptor. J Immunol 158:1490, 1997
28. Ding AH, Sanchez E, Srimal S, Nathan C: Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. J Biol Chem 264:3924, 1989.
29. Solomon KA, Covington MB, DeCicco CP: The fate of proTNFα following inhibition of metalloprotease-dependent processing to soluble TNFα in human monocytes. J Immunol 159:4524, 1997
30. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038, 1995
31. Pajkrt D, Camoglio L, Tiel-van Buul MCM, de Bruin K, Cutler DL, Affrime MB, Rikken G, van der Poll T, ten Cate JW, van Deventer SJH: Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia; the effect of timing of rhIL-10 administration. J Immunol 158:3971, 1997
32. Moss M, Becherer JD, Milla M, Pahel G, Lambert M, Andrews R, Frye S, Haffner C, Cowan D, Maloney P, Dixon EP, Jansen M, Vitek MP, Mitchell J, Leesnitzer T, Warner J, Conway J, Bickett DM, Bird M, Priest R, Reinhard J, Lin P: TNF convertase, in Bradshaw D, Nixon JS, Bottemley K (eds): Metalloproteinases as Targets for Anti-inflammatory Drugs. Basel, Switzerland, Birkhäuser Verlag, (in press)